Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 6 (2009), Issue 6 (June)

1. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
   Cancer Chemother Pharmacol, 64(2): 407-12. [Abstract] [Full-text]
2. Clinical outcomes of video-assisted thoracoscopic lobectomy.
   Mayo Clin Proc, 84(6): 509-13. [Abstract] [Full-text]
3. Local control of lung derived tumors by diffusing alpha-emitting atoms released from intratumoral wires loaded with radium-224.
   Int J Radiat Oncol Biol Phys, 74(3): 966-73. [Abstract] [Full-text]
4. Evaluation of linear accelerator gating with real-time electromagnetic tracking.
   Int J Radiat Oncol Biol Phys, 74(3): 920-7. [Abstract] [Full-text]
5. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient.
   Int J Cancer, 125(2): 474-82. [Abstract] [Full-text]
6. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor.
   Int J Cancer, 125(2): 381-7. [Abstract] [Full-text]
7. Time to treatment in patients with stage III non-small cell lung cancer.
   Int J Radiat Oncol Biol Phys, 74(3): 790-5. [Abstract] [Full-text]
8. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
   Cancer Chemother Pharmacol, 64(2): 371-7. [Abstract] [Full-text]
9. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
   Cancer Chemother Pharmacol, 64(2): 379-84. [Abstract] [Full-text]
10. Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer.
    Cancer Chemother Pharmacol, 64(2): 385-90. [Abstract] [Full-text]
11. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
    Cancer Chemother Pharmacol, 64(2): 401-6. [Abstract] [Full-text]
12. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
    Cancer Chemother Pharmacol, 64(2): 317-25. [Abstract] [Full-text]
13. TRAIL-induced apoptosis of FHIT-negative lung cancer cells is inhibited by FHIT re-expression.
    J Cell Physiol, 220(2): 492-8. [Abstract] [Full-text]
14. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population.
    Clin Cancer Res, 15(11): 3889-95. [Abstract] [Full-text]
15. Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
    Clin Cancer Res, 15(11): 3827-33. [Abstract] [Full-text]
16. Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population.
    Carcinogenesis, 30(6): 987-90. [Abstract] [Full-text]
17. Lung tumor promotion by curcumin.
    Carcinogenesis, 30(6): 1016-23. [Abstract] [Full-text]
18. Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice.
    Am J Respir Crit Care Med, 179(12): 1131-40. [Abstract] [Full-text]
19. Inhibition of nonneuronal alpha7-nicotinic receptor for lung cancer treatment.
    Am J Respir Crit Care Med, 179(12): 1141-50. [Abstract] [Full-text]
20. American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study.
    Chest, 135(6): 1619-27. [Abstract] [Full-text]
21. The in vitro and in vivo apoptotic effects of Mahonia oiwakensis on human lung cancer cells.
    Chem Biol Interact, 180(2): 165-74. [Abstract] [Full-text]
22. The selenium analog of the chemopreventive compound S,S'-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer.
    Chem Biol Interact, 180(2): 158-64. [Abstract] [Full-text]
23. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials.
    Chest, 135(6): 1596-609. [Abstract] [Full-text]
24. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
    Chest, 135(6): 1588-95. [Abstract] [Full-text]
25. Imprecision in automated volume measurements of pulmonary nodules and its effect on the level of uncertainty in volume doubling time estimation.
    Chest, 135(6): 1580-7. [Abstract] [Full-text]
26. Magnetic surface-enhanced Raman spectroscopic (M-SERS) dots for the identification of bronchioalveolar stem cells in normal and lung cancer mice.
    Biomaterials, 30(23): 3915-25. [Abstract] [Full-text]
27. Use of multidimensional data analysis for prediction of lung malignity.
    J Pharm Biomed Anal, 50(2): 210-5. [Abstract] [Full-text]
28. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma.
    Oncogene, 28(21): 2163-72. [Abstract] [Full-text]
29. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.
    Nat Cell Biol, 11(6): 694-704. [Abstract] [Full-text]
30. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
    Exp Cell Res, 315(12): 2022-32. [Abstract] [Full-text]
31. Stimulatory heterotrimeric GTP-binding protein augments cisplatin-induced apoptosis by upregulating Bak expression in human lung cancer cells.
    Cancer Sci, 100(6): 1069-74. [Abstract] [Full-text]
32. How to establish a solitary and localized VX2 lung cancer rabbit model? A simple and effective intrapulmonary tumor implantation technique.
    J Surg Res, 154(2): 284-92. [Abstract] [Full-text]
33. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Cancer Chemother Pharmacol, 64(3): 557-64. [Abstract] [Full-text]
34. Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
    Cancer Chemother Pharmacol, 64(3): 575-83. [Abstract] [Full-text]
35. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
    Cancer Chemother Pharmacol, 64(3): 539-48. [Abstract] [Full-text]
36. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Cancer Chemother Pharmacol, 64(3): 565-73. [Abstract] [Full-text]
37. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
    Cancer Chemother Pharmacol, 64(3): 463-72. [Abstract] [Full-text]
38. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis.
    Cancer Lett, 281(1): 32-41. [Abstract] [Full-text]
39. Screening and identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library.
    Cancer Lett, 281(1): 64-70. [Abstract] [Full-text]
40. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection.
    J Clin Oncol, 27(17): 2787-92. [Abstract] [Full-text]
41. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis.
    J Clin Oncol, 27(17): 2793-9. [Abstract] [Full-text]
42. Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase.
    J Control Release, 137(2): 110-5. [Abstract] [Full-text]
43. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
    Br J Cancer, 100(12): 1842-5. [Abstract] [Full-text]
44. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants.
    Proc Natl Acad Sci U S A, 106(23): 9385-90. [Abstract] [Full-text]
45. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.
    Br J Cancer, 100(12): 1949-56. [Abstract] [Full-text]
46. Optimisation and molecular signalling of apoptosis in sequential cryotherapy and chemotherapy combination in human A549 lung cancer xenografts in SCID mice.
    Br J Cancer, 100(12): 1896-902. [Abstract] [Full-text]
47. Rural reversal? Rural-urban disparities in late-stage cancer risk in Illinois.
    Cancer, 115(12): 2755-64. [Abstract] [Full-text]
48. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials.
    Cancer, 115(12): 2721-31. [Abstract] [Full-text]
49. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma.
    Cancer, 115(12): 2732-43. [Abstract] [Full-text]
50. Dose-response meta-analysis of silica and lung cancer.
    Cancer Causes Control, 20(6): 925-33. [Abstract] [Full-text]
51. Lung cancer in chrysotile asbestos workers: analyses based on the two-stage clonal expansion model.
    Cancer Causes Control, 20(6): 917-23. [Abstract] [Full-text]
52. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications.
    J Intern Med, 266(1): 43-52. [Abstract] [Full-text]
53. No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer.
    Mol Carcinog, 48(7): 581-5. [Abstract] [Full-text]
54. Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells.
    Mol Carcinog, 48(7): 662-70. [Abstract] [Full-text]
55. Ketoprofen in topical formulation decreases the matrix metalloproteinase-2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma.
    J Orthop Res, 27(7): 909-15. [Abstract] [Full-text]
56. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
    Am J Respir Cell Mol Biol, 41(1): 14-23. [Abstract] [Full-text]
57. Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients.
    Mol Carcinog, 48(7): 633-41. [Abstract] [Full-text]
58. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
    Cancer Res, 69(12): 5091-8. [Abstract] [Full-text]
59. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations.
    Cancer Res, 69(12): 5065-72. [Abstract] [Full-text]
60. Extended bronchoplasty and angioplasty with a right upper-middle bilobectomy and S6 segmentectomy for lung cancer: a novel technique for anastomosis.
    Gen Thorac Cardiovasc Surg, 57(6): 328-30. [Abstract] [Full-text]
61. Serum carcinoembryonic antigen level in non-small-cell lung cancer patients with preoperative normal serum level.
    Gen Thorac Cardiovasc Surg, 57(6): 303-6. [Abstract] [Full-text]
62. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
    J Clin Oncol, 27(18): 3014-9. [Abstract] [Full-text]
63. Risk factors involved in the development of pneumothorax during radiofrequency ablation of lung neoplasms.
    AJR Am J Roentgenol, 193(1): W43-8. [Abstract] [Full-text]
64. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer.
    Int J Cancer, 125(4): 887-93. [Abstract] [Full-text]
65. Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas.
    Int J Cancer, 125(4): 807-15. [Abstract] [Full-text]
66. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
    Eur J Cancer, 45(10): 1855-64. [Abstract] [Full-text]
67. The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer.
    Eur J Cancer, 45(10): 1773-9. [Abstract] [Full-text]
68. Dynamic changes in DNA methylation during multistep rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine.
    Toxicol Lett, 189(1): 5-13. [Abstract] [Full-text]
69. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
    Cancer Lett, 281(2): 134-43. [Abstract] [Full-text]
70. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway.
    Cancer Lett, 281(2): 213-9. [Abstract] [Full-text]
71. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Acta Radiol, 50(6): 638-44. [Abstract] [Full-text]
72. Effects of respiration-induced density variations on dose distributions in radiotherapy of lung cancer.
    Int J Radiat Oncol Biol Phys, 74(4): 1266-75. [Abstract] [Full-text]
73. Tumor localization using cone-beam CT reduces setup margins in conventionally fractionated radiotherapy for lung tumors.
    Int J Radiat Oncol Biol Phys, 74(4): 1100-7. [Abstract] [Full-text]
74. Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies.
    Int J Radiat Oncol Biol Phys, 74(4): 1092-9. [Abstract] [Full-text]
75. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 74(4): 1108-13. [Abstract] [Full-text]
76. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers.
    Nat Rev Cancer, 9(7): 476-88. [Abstract] [Full-text]
77. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Jpn J Clin Oncol, 39(7): 425-30. [Abstract] [Full-text]
78. Race and sex differences in the receipt of timely and appropriate lung cancer treatment.
    Med Care, 47(7): 774-81. [Abstract] [Full-text]
79. Inadequate access to surgeons: reason for disparate cancer care?
    Med Care, 47(7): 758-64. [Abstract] [Full-text]
80. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs.
    Proc Natl Acad Sci U S A, 106(25): 10290-5. [Abstract] [Full-text]
81. Inhibition of lung metastasis in mice by oligonol.
    Phytother Res, 23(7): 1043-6. [Abstract] [Full-text]
82. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation.
    Cancer Invest, 27(6): 624-35. [Abstract] [Full-text]
83. Is there a specific mutation of p53 gene due to radon exposure? A systematic review.
    Int J Radiat Biol, 85(7): 614-21. [Abstract] [Full-text]
84. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.
    J Steroid Biochem Mol Biol, 116(1): 102-9. [Abstract] [Full-text]
85. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
    Cancer Immunol Immunother, 58(9): 1397-405. [Abstract] [Full-text]
86. A unique case of ovarian psammocarcinoma with mediastinal, pulmonary, subcutaneous, and omental metastases.
    Arch Gynecol Obstet, 280(2): 283-6. [Abstract] [Full-text]
87. Use of a computer-aided detection system to detect missed lung cancer at chest radiography.
    Radiology, 252(1): 273-81. [Abstract] [Full-text]
88. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.
    Radiology, 252(1): 263-72. [Abstract] [Full-text]
89. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases.
    Cancer, 115(13): 2930-8. [Abstract] [Full-text]
90. Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification.
    Radiology, 252(1): 247-54. [Abstract] [Full-text]
91. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study.
    Cancer, 115(13): 2939-48. [Abstract] [Full-text]
92. A case of small cell lung cancer treated with chemoradiotherapy followed by photodynamic therapy.
    Thorax, 64(7): 637-9. [Abstract] [Full-text]
93. Severe hypoxemia due to intrapulmonary shunting requiring surgery for bronchioloalveolar carcinoma.
    Ann Thorac Surg, 88(1): 287-8. [Abstract] [Full-text]
94. Subclinical thrombosis of the ascending aorta: a possible paraneoplastic syndrome.
    Ann Thorac Surg, 88(1): 263-5. [Abstract] [Full-text]
95. The safe transition from open to thoracoscopic lobectomy: a 5-year experience.
    Ann Thorac Surg, 88(1): 216-25; discussion 225-6. [Abstract] [Full-text]
96. Surgical resection of pulmonary malignant tumors after living donor liver transplantation.
    Ann Thorac Surg, 88(1): 206-11. [Abstract] [Full-text]
97. Reconstruction of two independent neo-atria after resection of recurrent leiomyosarcoma.
    Ann Thorac Surg, 88(1): e1-2. [Abstract] [Full-text]
98. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    Lung Cancer, 65(2): 192-7. [Abstract] [Full-text]
99. Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features.
    Lung Cancer, 65(2): 247-50. [Abstract] [Full-text]
100. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
     Lung Cancer, 65(2): 251-3. [Abstract] [Full-text]
101. Dietary chemoprevention strategies for induction of phase II xenobiotic-metabolizing enzymes in lung carcinogenesis: A review.
     Lung Cancer, 65(2): 129-37. [Abstract] [Full-text]
102. Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer.
     Leuk Res, 33(9): 1208-11. [Abstract] [Full-text]
103. The detection of peripheral lung cancer by MAGE A1-6 RT-nested PCR in bronchial washing specimens.
     Lung Cancer, 65(2): 166-9. [Abstract] [Full-text]
104. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
     Lung Cancer, 65(2): 230-6. [Abstract] [Full-text]
105. Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT.
     Lung Cancer, 65(2): 180-6. [Abstract] [Full-text]
106. Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
     Lung Cancer, 65(2): 242-6. [Abstract] [Full-text]
107. Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication.
     Lung Cancer, 65(2): 223-9. [Abstract] [Full-text]
108. Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination.
     Lung Cancer, 65(2): 176-9. [Abstract] [Full-text]
109. Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer.
     Lung Cancer, 65(2): 161-5. [Abstract] [Full-text]
110. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature.
     Lung Cancer, 65(2): 214-8. [Abstract] [Full-text]
111. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
     Lung Cancer, 65(2): 237-41. [Abstract] [Full-text]
112. Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons.
     Lung Cancer, 65(2): 170-5. [Abstract] [Full-text]
113. Growth inhibition in antimycin A treated-lung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis.
     Lung Cancer, 65(2): 150-60. [Abstract] [Full-text]
114. Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
     Lung Cancer, 65(2): 204-7. [Abstract] [Full-text]
115. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
     Lung Cancer, 65(2): 187-91. [Abstract] [Full-text]
116. Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.
     Lung Cancer, 65(2): 208-13. [Abstract] [Full-text]
117. Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases.
     Lung Cancer, 65(2): 144-9. [Abstract] [Full-text]
118. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
     Lung Cancer, 65(2): 198-203. [Abstract] [Full-text]
119. Familial lung cancer risk among women in Poland.
     Lung Cancer, 65(2): 138-43. [Abstract] [Full-text]
120. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
     Lung Cancer, 65(2): 219-22. [Abstract] [Full-text]
121. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
     J Clin Oncol, 27(19): 3217-24. [Abstract] [Full-text]
122. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
     Gastroenterology, 137(1): 361-71, 371.e1-5. [Abstract] [Full-text]

© 2004-2010 Lung Cancer Research Today. All Rights Reserved.